Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 20, 2018
Event: Entry into a Material Definitive Agreement and Completion of Acquisition of Assets.
Key Financial Metrics and Transaction Details
This filing reports a specific acquisition transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins). The filing text does not provide a clear value for the company's overall financial position, debt levels, or liquidity outside of the transaction specifics.
| Metric | Value |
|---|---|
| Total Purchase Price | $14,200,000 |
| Cash Paid at Closing | $11,000,000 |
| Deferred Payment (12 months) | $2,000,000 |
| Deferred Payment (24 months) | $1,200,000 |
Material Changes and Transaction Scope
On September 20, 2018, the Company acquired the assets of the clot management business from Applied Medical Resources Corporation ("Applied"). The acquisition is not considered significant above the 20% level; therefore, financial statements of the acquired business are not required to be filed.
- Assets Acquired: Tangible assets, intellectual property, registrations and approvals, inventory, data, records, goodwill, and certain other assets.
- Non-Compete: Applied has agreed not to engage in certain competitive activities regarding the sold business or solicit Company employees for five years following the Closing Date.
- Transition Services: A one-year transition services agreement was entered into with an affiliate of Applied for the supply of acquired products.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance or outlook. Key contractual terms and risks include:
- Indemnification: Both parties are obligated to indemnify the other for breaches of representations, warranties, covenants, and certain liabilities or third-party claims.
- Future Obligations: The Company has committed to future cash outflows of $3,200,000 over the next 24 months to complete the purchase price payment.
Investor Verification Checklist
- Verify the integration timeline and expected revenue contribution of the clot management business assets.
- Review the upcoming Form 10-Q for the fiscal quarter ending September 30, 2018, for the full text of the Asset Purchase Agreement.
- Assess the impact of the $3.2 million deferred payment obligation on future cash flow projections.
- Confirm the terms of the one-year transition services agreement regarding product supply continuity.